Pressemitteilung BoxID: 786589 (Geratherm Medical AG)
  • Geratherm Medical AG
  • Fahrenheitstrasse 1
  • 98716 Geschwenda

Geratherm Medical announces preliminary financial figures 2015: Our best business year to date

(PresseBox) (Geschwenda, )
 Strong growth in sales and earnings
 Sales volume EUR 21.6 million +15.4 %
 Gross profit margin 65.4 % (2014: 64.4 %)
 EBITDA EUR 3.423 million +7.9 %; EBITDA margin 15.9 % (2014: 16.9 %)
 EBIT EUR 2.534 million +4.9 %; EBIT margin 11.7 % (2014: 12.9 %)
 Financial result 794 kEUR (2014: -164 kEUR).
 Results from ordinary business activities EUR 3.328 million (+47.8 %)
 Shareholder earnings (EAT) EUR 2.701 million (+60.6 %)
 Earnings per share 55 EUR cent (2014: 34 EUR cents)
 Proposed dividend 50 EUR cent per share (2014: 25 EUR cents)

Geratherm Medical was able to show for the 2015 fiscal year its best business performance so far with consolidated profits amounting to EUR 2.701 million. All product segments made a positive earnings contribution. The subsidiary Geratherm do Brasil had an unfavourable impact of -987 kEUR, where currency losses accounted for 488 kEUR, on the group's operating result for the period. The losses have already been compensated in the results reported above. We are anticipating that turnover and profit growth will continue for 2016.

The in-depth annual report will be published on 26 April 2016.

Geratherm Medical AG

Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.